460 results on '"Cardona, Andrés F."'
Search Results
2. Facing an un-met need in lung cancer screening: The never smokers
3. Prevalence of pathogenic or likely pathogenic germline variants in cancer predisposition genes among selected patients with lung adenocarcinoma: The GERMLUNG study
4. Cost-utility analysis of genomic profiling in early breast cancer in Colombia
5. Cost-Effectiveness of Comprehensive Genomic Profiling in Patients With Non–Small Cell Lung Cancer for the Colombian Health System
6. Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma
7. Impact of Concurrent Genomic Alterations on Clinical Outcomes in Patients With ALK-Rearranged NSCLC
8. Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study
9. Molecular Tumor Board Improves Outcomes for Hispanic Patients With Advanced Solid Tumors
10. Nitroglycerin Plus Whole Intracranial Radiation Therapy for Brain Metastases in Patients With Non-Small Cell Lung Cancer: A Randomized, Open-Label, Phase 2 Clinical Trial
11. Dendritic cells and glioblastoma
12. Contributors
13. A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population
14. Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP)
15. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP)
16. Clinical and pathological characteristics associated with the presence of the IS6110 Mycobacterim tuberculosis transposon in neoplastic cells from non-small cell lung cancer patients
17. Sarcopenia as a Predictive Factor for Carboplatin Toxicity in Patients with Advanced Non-Small Cell Lung Cancer.
18. Early Incorporation to Palliative Care (EPC) in Patients With Advanced Non-Small Cell Lung Cancer: The PACO Randomized Clinical Trial.
19. ADAURA: redefining the role of target therapy in resectable lung adenocarcinoma
20. Association of Carcinoembryonic Antigen Reduction With Progression-free and Overall Survival Improvement in Advanced Non-small-cell Lung Cancer
21. Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean
22. How clinically useful is comprehensive genomic profiling for patients with non-small cell lung cancer? A systematic review
23. Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation
24. Prophylactic Cranial Irradiation Reduces Brain Metastases and Improves Overall Survival in High-Risk Metastatic Non-Small Cell Lung Cancer Patients: A Randomized phase 2 Study (PRoT-BM trial)
25. The Effects of Angiotensin-Converting Enzyme Inhibitors on Metastasis-Associated Myeloid Cells
26. When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review
27. Ischemic stroke: A paradoxical manifestation of cancer
28. Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID‐19 pandemic: the THOCOoP cooperative group
29. Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)
30. Lung cancer in never smokers: The role of different risk factors other than tobacco smoking
31. Mentoring as an opportunity to improve research and cancer care in Latin America (AAZPIRE project)
32. Bilateral Lumbosacral Plexopathy As the Initial Manifestation of Systemic Sarcoidosis: A Case Report
33. PD-L1 expression complements CALGB prognostic scoring system in malignant pleural mesothelioma
34. Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells
35. Impact of KRASG12D subtype and concurrent pathogenic mutations on advanced non-small cell lung cancer outcomes.
36. Treatment for Advanced Non–Small Lung Cancer (NSCLC) with Mutated EGFR in Low- and Middle-Income Countries (LMICs)
37. Perilesional edema diameter associated with brain metastases as a predictive factor of response to radiotherapy in non-small cell lung cancer
38. EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP)
39. Impact of the COVID-19 Pandemic on Oncology Clinical Research in Latin America (LACOG 0420)
40. Impact of KRASG12D subtype and concurrent pathogenic mutations on advanced non-small cell lung cancer outcomes
41. Differential gene expression profiles according to the Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society histopathological classification in lung adenocarcinoma subtypes
42. Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study
43. EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP)
44. Supplementary Figures 1 - 10, Tables 1 - 11 from Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer
45. Case report: Osimertinib administration during pregnancy in a woman with advanced EGFR-mutant non-small cell lung cancer
46. DICER1-associated central nervous system sarcoma: A comprehensive clinical and genomic characterization of case series of young adult patients
47. Depatuxizumab-mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial
48. Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015
49. Management of diarrhea induced by EGFR-TKIs in advanced lung adenocarcinoma
50. LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.